ACM
EW icon

Atika Capital Management’s Edwards Lifesciences EW Stock Holding History

Atika Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,200
Closed -$8.88M – 71
2024
Q4 		$8.88M Buy
+1,200
New +$84K 0.94% 33

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Atika Capital Management's EW Position: Q4 2022 in Review

Atika Capital Management sold out of Edwards Lifesciences (EW) in Q4 2022, closing a stake of 29,000 shares — an estimated $2.4M sold.

Atika Capital Management first reported a position in EW in Q1 2015 and held it in 6 quarters. The position peaked at $4.1M in Q3 2016. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2022.

  • Atika Capital Management reported no remaining Edwards Lifesciences position as of Q4 2022 after selling out during the quarter.
  • Atika Capital Management sold 29,000 Edwards Lifesciences shares in Q4 2022, an estimated $2.4M.
  • Atika Capital Management first reported a position in Edwards Lifesciences in Q1 2015 and held it in 6 quarters.
  • Atika Capital Management's Edwards Lifesciences position peaked at $4.1M in Q3 2016.
  • 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2022.

Based on Atika Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.